Fzata's novel platform modality for oral biologics is Bioengineered Probiotic Yeast Medicines (BioPYM) with over 10 GI drug candidates.
Fzata, Inc.'s investors include National Institute of Neurological Disorders and Stroke.
Fzata, Inc. is headquartered in Halethorpe, United States.
Fzata's novel platform modality for oral biologics is Bioengineered Probiotic Yeast Medicines (BioPYM) with over 10 GI drug candidates.
Fzata, Inc. is at the Grant stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Fzata, Inc. — Funding & Investors." VCBacked, September 24, 2024, https://www.vcbacked.co/company/fzata-inc. Accessed October 1, 2026.
VCBacked. (2024). Fzata, Inc. — Funding & Investors. Retrieved October 1, 2026, from https://www.vcbacked.co/company/fzata-inc
{{cite web |title=Fzata, Inc. — Funding & Investors |url=https://www.vcbacked.co/company/fzata-inc |website=VCBacked |access-date=October 1, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated